SCHEMBL7148276

SCHEMBL7148276

COc1ccc(CSC2CC(C(C)=O)N(S(=O)(=O)c3ccc4ccccc4c3)C2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MMP1 P03956 15/20 0.43
MMP13 P45452 14/20 0.43
MMP3 P08254 11/20 0.43
MMP2 P08253 9/20 0.43
MMP7 P09237 8/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
MME P08473 2/20 0.41
ACE P12821 2/20 0.41
ECE1 P42892 2/20 0.41
MMP9 P14780 9/20 0.41
ADAM17 P78536 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148270 1.00 ALDH1A1 (0.48) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5723539 0.93 CA12 (0.49) ALDH1A1LMNAGAAPKMHTT
SCHEMBL6977450 0.92 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5723279 0.92 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7141010 0.91 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7139058 0.91 ALDH1A1 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5722900 0.89 MMP3 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5723766 0.89 MMP3 (0.47) ALDH1A1LMNAGAAPKMHTT
SCHEMBL7150109 0.89 MME (0.45) ALDH1A1LMNAGAAPKMHTT
SCHEMBL5723235 0.89 MME (0.45) ALDH1A1LMNAGAAPKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885LMNA 4821/4885GAA 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.